What Is a 510(k)? FDA Clearance Explained for MedTech Teams
2026-09-26 · Caduvo Team
A complete guide to the FDA 510(k) premarket notification pathway: substantial equivalence, eSTAR requirements, review timelines, fees, and clearance rules.
Medical device founders often say their product is "FDA approved" when it is actually cleared. The distinction is not semantic. It dictates your regulatory pathway, bench testing requirements, and clinical evidence strategy. The Premarket Notification, universally referred to as a 510(k), serves as the primary regulatory gateway the Food and Drug Administration uses to review moderate-risk medical hardware and software entering the United States commercial market.
Understanding what is a 510k requires understanding comparative review. Rather than establishing safety and effectiveness entirely through standalone premarket clinical trials, a 510(k) demonstrates that a device performs as safely and effectively as an existing legally marketed benchmark. Knowing how the agency evaluates these submissions keeps your team from misallocating capital on misaligned testing protocols or misinterpreting statutory review requirements.
Who Needs a 510(k) and Who Does Not
The FDA regulates medical devices under a risk-based framework established by Congress in the Medical Device Amendments of 1976, which were incorporated into the Federal Food, Drug, and Cosmetic Act (FD&C Act). According to FDA device classification data, devices fall into three distinct classes based on the degree of control necessary to assure safety and effectiveness:
- Class I (Low Risk): Accounting for roughly 47% of all medical devices, Class I products present minimal harm to the user and are simpler in design. About 95% of Class I devices are exempt from premarket review. Items like manual stethoscopes, bedpans, mercury thermometers, enema kits, and elastic bandages require establishment registration and generic product listing rather than a premarket notification.
- Class II (Moderate Risk): Comprising approximately 43% of devices, Class II includes powered wheelchairs and certain pregnancy test kits. Most Class II products require fda 510k clearance before a manufacturer can introduce them into commercial distribution.
- Class III (High Risk): Representing roughly 10% of devices, Class III encompasses products that sustain or support life, are implanted, or present a potential unreasonable risk of illness or injury, such as implantable pacemakers and breast implants. These products generally require Premarket Approval (PMA), an independent demonstration of safety and effectiveness rather than a comparison to a predicate.
Under 21 CFR Part 807 Subpart E, a manufacturer must file a 510k submission when introducing a device to the U.S. market for the first time. Section 510(k) of the FD&C Act requires entities to notify the FDA of their intent to market at least 90 days in advance. A new submission is also required when reintroducing a device that undergoes significant modifications in design, materials, chemical composition, energy source, manufacturing process, or indications for use that could affect its safety or effectiveness.
Certain commercial arrangements modify these obligations. Under 21 CFR 801.1(c), distributors do not submit a 510(k) for an existing product they distribute under their own label. The label must include phrasing such as "Distributed by ABC Company" or "Manufactured for ABC Company," while complaint handling remains governed by 21 CFR 820.198. As outlined in FDA 510(k) guidance, a new company that does not manufacture any medical devices should not register its facility until it is within 30 days of manufacturing and distributing the device. The initial 510(k) filing must state that the company is not currently registered.
Substantial Equivalence: Cleared vs. Approved
The statutory standard for obtaining a 510(k) clearance is establishing substantial equivalence (SE). Under section 513(i)(1)(A) of the FD&C Act, a 510(k) is a premarket notification made to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device. Submitters must compare their device to one or more similar legally marketed devices and support their substantial equivalence claims with objective data.
A legally marketed predicate device can be a preamendments device legally marketed prior to May 28, 1976, a device cleared through the 510(k) pathway, a product originally on the market as a Class III device that was downclassified to Class II or Class I, or a 510(k) exempt device. According to FDA predicate device criteria, almost all modern submissions compare their candidate to a postamendments device recently cleared under 510(k). The predicate must be legally marketed, meaning it cannot violate the FD&C Act, though an applicant may cite a predicate that is no longer actively marketed in the U.S.
A claim of substantial equivalence does not mean the devices must be identical. As established by FDA guidance, substantial equivalence is evaluated across intended use, design, energy used or delivered, materials, performance, safety, effectiveness, labeling, biocompatibility, standards, and other applicable characteristics. When differences exist between the candidate device and the predicate, the manufacturer must provide scientific performance testing demonstrating that these differences do not diminish safety or effectiveness.
This comparative mechanism explains why 510(k) devices are "cleared" rather than "approved." The FDA issues an order in the form of a letter clearing the device for commercial distribution once substantial equivalence is established. Marketing a 510(k) device as "FDA approved" misrepresents its regulatory status under federal law, as approval is reserved for Class III PMA submissions. If a novel moderate-risk device has no valid predicate, the 510(k) route cannot be used, requiring the team to evaluate the De Novo classification pathway.
Structure of an eSTAR 510(k) Submission
Premarket notifications have transitioned away from disparate paper files and standalone PDF assemblies. On October 3, 2022, the FDA introduced electronic uploads through the CDRH Customer Collaboration Portal. Effective October 1, 2023, all non-exempt 510(k) submissions must be submitted as electronic submissions using the electronic Submission Template And Resource (eSTAR) format.
The eSTAR framework structures technical documentation to address the elements defined in 21 CFR 807 Subpart E. A complete filing includes:
- Administrative Information: Device trade name, common name, classification regulation (such as regulations found in 21 CFR 862 or 864), product code, and submitter contact information. Foreign entities can submit directly to the FDA or identify a designated U.S. agent.
- Indications for Use: The specific clinical condition, target patient population, anatomical site, and environment of use that define the device's operational scope.
- Device Description: Detailed schematics, dimensional drawings, operating principles, physical assemblies, and material formulations.
- Substantial Equivalence Comparison: A technical side-by-side comparison detailing how the candidate matches the chosen predicate across intended use, design, materials, energy delivered or used, and operational performance.
- Non-Clinical Performance Testing: Bench mechanical assessments, electrical safety, electromagnetic compatibility, sterility validation, shelf-life testing, and biocompatibility evaluations addressing patient-contacting components.
- Software and Cybersecurity: Architecture diagrams, risk management documentation, verification and validation summaries, and cybersecurity controls when digital components or connected hardware are present.
- Proposed Labeling: Package labels, instructions for use, surgical manuals, and user guides.
Clinical trials are rarely needed for standard premarket notifications. Per FDA premarket review criteria, only a small percentage of 510(k) submissions require clinical data. When analytical bench data or animal models cannot prove equivalence for technological characteristics, the sponsor must conduct human clinical testing under an Investigational Device Exemption (IDE).
Timelines, Fees, and Common Review Deficiencies
Section 510(k) of the FD&C Act requires submitters to notify the agency at least 90 days in advance of introducing a device into commercial distribution. The FDA charges a fee for reviewing Premarket Notifications. Filings submitted through the CDRH Portal undergo an initial intake review to confirm completeness under the agency's Refuse to Accept (RTA) policy.
During substantive review, the FDA may issue an Additional Information (AI) request if the documentation does not fully demonstrate substantial equivalence. Reviewers examine specific technical areas where deficiencies commonly arise:
- Mismatched Indications for Use: Introducing wording that alters the intended clinical condition, patient population, or operational setting compared to the predicate, which can undermine the substantial equivalence claim.
- Inadequate Predicate Comparison: Providing high-level descriptions rather than side-by-side quantitative comparisons detailing device design, energy characteristics, and materials.
- Incomplete Performance Testing: Submitting test summaries that omit clear rationales, fail to identify specific consensus standards, or lack clear pass/fail acceptance criteria for mechanical durability, electrical safety, or biocompatibility.
- Quality System Documentation Errors: Standard 510(k) submissions do not require documentation showing that a facility complies with the Quality System regulation, nor is a pre-clearance facility inspection a prerequisite to 510(k) clearance. However, if submitting a Special 510(k), the manufacturer must provide a declaration of conformity with the design controls aspect of the Quality System.
Regulatory planning must occur alongside commercial access planning. Securing 510(k) clearance allows legal marketing, but it does not guarantee payer reimbursement. Teams can evaluate existing CPT and HCPCS codes, payer coverage determinations, and predicate reimbursement precedent through platforms like Caduvo early in product development so that cleared indications support commercial adoption.
Actionable 510(k) Milestones for Device Founders
To keep your clearance pathway on schedule, execute these operational steps:
- Identify your classification regulation: Review the FDA 510(k) database to determine whether your product maps to a Class II classification regulation and identify historical clearances in that product code.
- Examine predicate clearance history: Confirm that your chosen predicate was legally marketed prior to May 28, 1976, cleared through the 510(k) pathway, downclassified from Class III to Class II or Class I, or is a 510(k) exempt device.
- Build within the eSTAR template: Prepare submission materials directly inside the current eSTAR electronic structure rather than drafting disconnected documents for later reformatting.
- Assess alternative pathways if predicates are lacking: If your moderate-risk device involves novel intended uses or mechanisms that have no predicate benchmark, evaluate the De Novo classification request pathway under the FD&C Act.
- Coordinate labeling with commercial access: Ensure your indications for use match the clinical evidence needed by hospital value analysis committees and commercial insurers, avoiding overly restrictive language that complicates downstream billing.
Sources
- Premarket Notification 510(k) | FDA
- Medical Device Safety and the 510(k) Clearance Process | FDA
- 510(k) Clearances | FDA
- Learn if a Medical Device Has Been Cleared by FDA for Marketing | FDA
- How to Find and Effectively Use Predicate Devices | FDA
- 510(k) Frequently Asked Questions | FDA
General information, not regulatory, legal or reimbursement advice. Company and product names belong to their owners; a mention does not imply affiliation or endorsement. Report an error. Data and corrections policy.